4.6 Article

Sex Differences in Demographics, Risk Factors, Presentation, and Noninvasive Testing in Stable Outpatients With Suspected Coronary Artery Disease

Journal

JACC-CARDIOVASCULAR IMAGING
Volume 9, Issue 4, Pages 337-346

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcmg.2016.02.001

Keywords

angina; CAD; risk factors; sex

Funding

  1. National Heart, Lung, and Blood Institute [R01 HL098237, R01 HL098236, R01 HL098305, R01 HL098235]
  2. Medtronic
  3. CardioDx
  4. St. Jude Medical
  5. Eli Lilly
  6. Bristol-Myers Squibb
  7. Gilead Sciences
  8. AGA Medical
  9. Merck
  10. Oxygen Biotherapeutics
  11. AstraZeneca
  12. Siemens Healthcare
  13. HeartFlow

Ask authors/readers for more resources

OBJECTIVES The aim of this study was to determine whether presentation, risk assessment, testing choices, and results differ by sex in stable symptomatic outpatients with suspected coronary artery disease (CAD). BACKGROUND Although established CAD presentations differ by sex, little is known about stable, suspected CAD. METHODS The characteristics of 10,003 men and women in the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial were compared using chi-square and Wilcoxon rank-sum tests. Sex differences in test selection and predictors of test positivity were examined using logistic regression. RESULTS Women were older (62.4 years of age vs. 59.0 years of age) and were more likely to be hypertensive (66.6% vs. 63.2%), dyslipidemic (68.9% vs. 66.3%), and to have a family history of premature CAD (34.6% vs. 29.3) (all p values<0.005). Women were less likely to smoke (45.6% vs. 57.0%; p<0.001), although their prevalence of diabetes was similar to that in men(21.8% vs. 21.0%; p = 0.30). Chest pain was the primary symptomin 73.2% of women versus 72.3% of men (p = 0.30), and was characterized as crushing/pressure/ squeezing/tightness in 52.5% of women versus 46.2% of men (p<0.001). Compared with men, all risk scores characterized women as being at lower risk, and providers were more likely to characterize women as having a low (<30%) pre-test probability of CAD (40.7% vs. 34.1%; p < 0.001). Compared with men, women were more often referred to imaging tests (adjusted odds ratio: 1.21; 95% confidence interval: 1.01 to 1.44) than nonimaging tests. Women were less likely to have a positive test (9.7% vs. 15.1%; p < 0.001). Although univariate predictors of test positivity were similar, in multivariable models, age, body mass index, and Framingham risk score were predictive of a positive test in women, whereas Framingham and Diamond and Forrester risk scores were predictive in men. CONCLUSIONS Patient sex influences the entire diagnostic pathway for possible CAD, from baseline risk factors and presentation to noninvasive test outcomes. These differences highlight the need for sex-specific approaches for the evaluation of CAD. (C) 2016 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available